Program
opevesostat
Also written as “Opevesostat”, “MK-5684” and “ODM-208”.
Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant · Neoplasms · Kidney Failure, Chronic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 124 open or running | phase 3since Nov 13, 2023 | Oct 23, 2023 | Nov 4, 2027phase 2 · NCT06979596 |
| Orion Corporation, Orion Pharma | 11 open or running | phase 2since Feb 12, 2018 | Feb 12, 2018 | none ahead |
- Named in Merck’s own pipeline as
opevesostat (MK-5684)
, phase 3, as of Nov 2, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 12, 2018First study: phase 2 study in Prostate Cancer MetastaticNew to Orion Corporation, Orion PharmaOrion Corporation, Orion Pharma · NCT03436485 · 204 enrolled · United States, Finland, France and more
- Oct 23, 2023Merck's first study: phase 1 study in Prostatic NeoplasmsNew to MerckMerck · NCT06104449 · 7 enrolled · Japan
- Nov 13, 20232 phase 3 studiesMerck · NCT06136650, NCT06136624
- Nov 13, 2023Phase 1 study in Prostatic NeoplasmsMerck · NCT06136598 · 14 enrolled · China
- Apr 3, 2024Phase 2 study in Prostatic Neoplasms, Castration-ResistantMerck · NCT06353386 · 220 enrolled · United States, Australia, Canada and more
- Aug 12, 20242 phase 1 studies in Prostatic NeoplasmsMerck · NCT06554639, NCT06566989
- Oct 7, 2024Phase 1 study in HealthyMerck · NCT06633419 · 14 enrolled · United States
- Feb 3, 20252 phase 1 studiesMerck · NCT06814132, NCT06860243
- May 13, 2025Phase 2 study in NeoplasmsMerck · NCT06979596 · 250 planned · United States, Argentina, Brazil and more
- Apr 17, 2026Phase 1 study in HealthyMerck · NCT07548606 · 14 enrolled · United States
- Nov 5, 2026Primary completion moved from 2028-08-02 to 2028-11-30Date moved laterphase 3 · +4 months · NCT06136624
Ahead
- Nov 4, 2027Primary completion: phase 2 study in NeoplasmsMerck · NCT06979596
- May 10, 2028Primary completion: phase 3 study in Prostatic NeoplasmsMerck · NCT06136650
- Nov 30, 2028Primary completion: phase 3 study in Prostate Cancer MetastaticMerck · NCT06136624
- Jan 15, 2029Primary completion: phase 2 study in Prostatic Neoplasms, Castration-ResistantMerck · NCT06353386
TargetBeta
“An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), with potential antineoplastic activity. Upon oral administration, opevesostat targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all ste…”NCIt, read by Claude
“An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), ”NCIt, by rule
Other programs on CYP11A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| CYP11A1 Inhibitor ACE-232rule | acerand-therapeutics-hong-kong-limited | phase 1 | 1 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07548606Healthy · United States | 1 | Completed | Merck | Jun 1, 2026 | 14 |
| NCT06979596Neoplasms · United States, Argentina, Brazil and more | 2 | Recruiting | Merck | Nov 4, 2027 | 250 |
| NCT06860243Hepatic Impairment · United States | 1 | Completed | Merck | Feb 9, 2026 | 16 |
| NCT06814132Kidney Failure, Chronic · United States | 1 | Completed | Merck | Oct 4, 2025 | 24 |
| NCT06633419Healthy · United States | 1 | Completed | Merck | Feb 12, 2025 | 14 |
| NCT06566989Prostatic Neoplasms · United Kingdom | 1 | Completed | Merck | Oct 17, 2024 | 8 |
| NCT06554639Prostatic Neoplasms · United States | 1 | Completed | Merck | Aug 5, 2024 | 12 |
| NCT06353386Prostatic Neoplasms, Castration-Resistant · United States, Australia, Canada and more | 2 | Active, not recruiting | Merck | Jan 15, 2029 | 220 |
| NCT06136650Prostatic Neoplasms · United States, Australia, Brazil and more | 3 | Recruiting | Merck | May 10, 2028 | 1,314 |
| NCT06136624Prostate Cancer Metastatic · United States, Argentina, Australia and more | 3 | Recruiting | Merck | Nov 30, 2028 | 1,310 |
| NCT06136598Prostatic Neoplasms · China | 1 | Completed | Merck | Mar 9, 2026 | 14 |
| NCT06104449Prostatic Neoplasms · Japan | 1 | Completed | Merck | Feb 20, 2026 | 7 |
| NCT03436485Prostate Cancer Metastatic · United States, Finland, France and more | 2 | Active, not recruiting | Orion Corporation, Orion Pharma | Oct 31, 2026 | 204 |
How it is read
Names in the registry
- “Opevesostat”, 9 entries
- “MK-5684”, 2 entries
- “ODM-208”, 1 entry
- “[¹⁴C]Opevesostat”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 7 studies
- Prostatic Neoplasms, Castration-Resistant, 1 study
- Neoplasms, 1 study
- Kidney Failure, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.